Avanos Medical, Inc. (AVNS)

In the past six months, Avanos Medical's stock has increased by 120.8% since the beginning of 2026 and reached a 52-week high. Key events include the Q1 2026 Earnings Report, which showed an increase in net sales but a decline in net income, and the announcement of a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP). Following the acquisition announcement, several law firms initiated investigations into whether Avanos Medical, Inc. is obtaining a fair price for its public shareholders.

Explicit information regarding overall demand seasonality for Avanos Medical's products and services is not readily available. However, Q2 2025 results indicated strong demand and volume across the Specialty Nutrition Systems portfolio and positive momentum in radiofrequency ablation generator sales, which was partially offset by lower volume in the surgical pain and recovery portfolio. Avanos Medical also participates in various medical conferences throughout the year.

Avanos Medical, Inc. operates in the Healthcare sector, focusing on Healthcare Equipment & Supplies and Medical Devices. The company has two primary franchises: Pain Management and Chronic Care. Its product offerings include Digestive Health Products, Non-Opioid Pain Solutions, Interventional Pain Solutions, and Respiratory Health Products.

Avanos Medical, headquartered in Alpharetta, Georgia, has a significant global presence, providing medical device solutions across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company markets its products directly to hospitals, healthcare providers, and facilities, and also utilizes third-party wholesale distributors. Avanos Medical develops, manufactures, and markets its brands in over 90 countries and operates 8 principal medical device production facilities worldwide.

In the past year, no specific negative events significantly impacted Avanos Medical's brand reputation. A past event from April 2022 involved a voluntary field correction for a hospital tool. Avanos Medical announced in May 2025 that it would expand its direct operations for MIC-KEY enteral feeding products in the United Kingdom starting July 2025.

Avanos Medical's ownership is largely dominated by institutional investors, who collectively held approximately 94.60% of the company's shares as of May 2025. Insiders account for a smaller portion, around 2.02%. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., and T. Rowe Price Investment Management, Inc.